Models for Pancreatic Cancer

PANC-1 PANC-1 was isolated from a 56-year-old Caucasian man with pancreatic ductal adenocarcinoma. Subcutaneous tumor growth is reliable and consistent, with tumor volume doubling every 5 days and typically reaching evaluation size (~750mm3) in approximately 29 days post implant. Treatment with gemcitabine (160mg/kg) is well tolerated and produces statistically significant […]

The State of Modeling Preclinical Immuno-Oncology Pharmacology

The field of cancer immunology or immuno-oncology (I/O) dates back to the 1890’s with efforts by William Coley to treat malignancies by infection with certain bacterial strains.1 Fast forward 120 years, and we have observed the clinical success of multiple checkpoint inhibitor antibodies against cancer specific T cell negative regulatory pathways in multiple cancer types.2 […]